Columbia Labs (CBRX) Completes 1.3M Share Offering; Raises $4.1M in Net Proceeds
More News related to CBRX
- "CRINONE(R) 8% (progesterone vaginal gel) As Effective as Hormone Injections During IVF" Is Medscape's "Top News" from The ASRM 65th Annual Meeting
- Columbia Laboratories Reports Third Quarter 2009 Financial Results
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Columbia Laboratories Closes Registered Direct Common Stock and Warrant Offering
- Columbia Laboratories to Present at the Oppenheimer 20th Annual Healthcare Conference on November 3, 2009
Columbia Laboratories, Inc. (Nasdaq: CBRX) has raised approximately $4.7 million in gross proceeds to the Company through the sale of approximately 1.3 million shares of its common stock at a price of $3.50 per share in a registered direct offering.
Net proceeds are expected to be approximately $4.1 million after offering-related fees and expenses. Columbia intends to use the net proceeds from the offering for general corporate purposes, including funding its clinical development and other research and development activities, internal and/or collaborative sales, marketing and distribution expenditures, capital expenditures and working capital needs.
Columbia Laboratories, Inc. engages in the research, development, manufacture, and commercialization of women's healthcare and endocrinology products. I
Related Categories
Equity OfferingsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
